Global R&D Pipeline
My Favorite
Hot Targets:
CD98HC
Back
Total number of drugs
16
Phase II and later clinical stages
0%
Involving companies
20
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MAb52-4.2 | MAb52-4.2 | Monoclonal antibody | Neoplasms Hemic and Lymphatic Diseases | SLC3A2 modulators | Medabome, Inc. | Medabome, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | MAb52-4.2 | - | - | detail > | |
| 211At-TLX-102 | 211At-TLX-102 | Small molecule drug Therapeutic radiopharmaceuticals | Neoplasms Nervous System Diseases | SLC3A2 inhibitors SLC7A5 inhibitors | Telix Pharmaceuticals Ltd. | Telix Pharmaceuticals Ltd. | Preclinical | - | - | - | - | Orphan Drug（United States） | - | - | 211 At | - | 211At-TLX-102 | - | - | detail > | |
| c-SF-25 Mab(Kagoshima University) | c-SF-25 Mab(Kagoshima University) | Monoclonal antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | SLC3A2 inhibitors | Kagoshima University | Kagoshima University | Preclinical | - | - | - | - | - | - | - | - | - | c-SF-25 Mab(Kagoshima University) | - | - | detail > | |
| NPB15 | NPB15 | Monoclonal antibody | Neoplasms Digestive System Disorders | SLC3A2 inhibitors | Sejong University | Sejong University | Preclinical | - | - | - | - | - | - | - | - | - | NPB15 | - | - | detail > | |
| HH018-sesutecan | HH018-sesutecan | Antibody drug conjugate (ADC) | Neoplasms | SLC3A2 inhibitors | Huahui Health Ltd. | Huahui Health Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | HH018-sesutecan | - | - | detail > | |
| CN117561276 | CN117561276 | Monoclonal antibody | Neoplasms Skin and Musculoskeletal Diseases | - | Huahui Health Ltd. | Huahui Health Ltd. | Discovery | - | - | - | - | - | - | - | - | - | CN117561276 | - | - | detail > | |
| WO2025055904 | WO2025055904 | Antibody | Nervous System Diseases Cardiovascular Diseases | - | Fubei Biotechnology Suzhou Co. Ltd. 4B Technologies (Beijing) Co., Limited | 4B Technologies (Beijing) Co., Limited Fubei Biotechnology Suzhou Co. Ltd. | Discovery | - | - | - | - | - | - | - | - | - | WO2025055904 | - | - | detail > | |
| CN115698074 | CN115698074 | Antibody | Nervous System Diseases | - | Aliada Therapeutics, Inc. | Aliada Therapeutics, Inc. | Discovery | - | - | - | - | - | - | - | - | - | CN115698074 | - | - | detail > | |
| WO2024028732 | WO2024028732 | Bispecific antibody | Neoplasms | - | Janssen Biotech, Inc. | Janssen Biotech, Inc. | Discovery | - | - | - | - | - | - | - | - | - | WO2024028732 | - | - | detail > | |
| CN118324863 | CN118324863 | Monoclonal antibody | Neoplasms Digestive System Disorders | - | Tianjin Medical University Cancer Institute and Hospital | Tianjin Medical University Cancer Institute and Hospital | Discovery | - | - | - | - | - | - | - | - | - | CN118324863 | - | - | detail > |
Total 16 data
1
2
